Thanks for your feedback, always appreciated. I got the feeling that you knew how to back a winner
I've just reviewed my estimate again, and it looks like I had overestimated the R&D expenses. It doesn't make sense that R&D expenses this year would be more than last year now that the two main clinical trials have been completed and development was completed on RECELL GO during Q2 so I've adjusted that down. Once I take another million out for the one-off G&A expenses in Q1 (thanks @avetis, I'd only taken $1m out for severance pay outs), I'm within the range of your and Cantor-Fitzgerald estimates which is reassuring
Another issue with my estimate that I can see now is that the peak in opex/revenue is in Q123 instead of the Q323 guidance. If the peak has been brought forward, it would be a good outcome. Anyway, we'll have an better idea in a month when results are announced.
Thanks for your feedback, always appreciated. I got the feeling...
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.66 |
Change
-0.060(2.21%) |
Mkt cap ! $184.2M | |||
| Open | High | Low | Value | Volume |
| $2.73 | $2.73 | $2.66 | $321.5K | 120.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1499 | $2.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.70 | 50 | 1 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| AVH (ASX) Chart |